WELLINGTON MANAGEMENT CO LLP 13D and 13G filings for Alnylam Pharmaceuticals, Inc.:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company's equity securities.
- Shares have been adjusted for stock splits.
| Reported DateTime |
Transaction Date |
Type | Company Symbol |
Filed By Symbol |
Shares Owned % Owned |
Shares Vs. Prev Report | View |
| 2024-11-08 10:34 am Sale |
2024-09-30 | 13G | Alnylam Pharmaceuticals, Inc. ALNY |
WELLINGTON MANAGEMENT CO LLP | 5,018,779 3.910% |
-2,234,128 (-30.80%) |
Filing |
| 2024-02-09 08:40 am Purchase |
2023-12-29 | 13G | Alnylam Pharmaceuticals, Inc. ALNY |
WELLINGTON MANAGEMENT CO LLP | 7,252,907 5.780% |
991,265 (+15.83%) |
Filing |
| 2023-02-06 2:43 pm Sale |
2022-12-30 | 13G | Alnylam Pharmaceuticals, Inc. ALNY |
WELLINGTON MANAGEMENT CO LLP | 6,261,642 5.090% |
-578,179 (-8.45%) |
Filing |
| 2022-02-04 09:12 am Sale |
2021-12-31 | 13G | Alnylam Pharmaceuticals, Inc. ALNY |
WELLINGTON MANAGEMENT CO LLP | 6,839,821 5.720% |
-3,217,119 (-31.99%) |
Filing |
| 2021-02-03 1:33 pm Sale |
2020-12-31 | 13G | Alnylam Pharmaceuticals, Inc. ALNY |
WELLINGTON MANAGEMENT CO LLP | 10,056,940 8.660% |
-4,229,534 (-29.61%) |
Filing |